Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy

The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxiciti...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of hematology and oncology 2019-11, Vol.12 (1), p.128-128, Article 128
Main Authors:	Han, Xiao, Wang, Yao, Wei, Jianshu, Han, Weidong
Format:	Article
Language:	eng
Subjects:	Antigen escape Antigens Antimitotic agents Antineoplastic agents Automobiles Axicabtagene ciloleucel Cancer Cancer therapies Cancer treatment Care and treatment Chimeric antigen receptor T cells Chimeric antigen receptors Clinical trials Genetic engineering Health aspects Hematology Immunotherapy Logic gate Lymphocytes Lymphocytes T Mutation Off-tumor toxicities On-target Oncology Review T cell receptors T cells Tisagenlecleucel Toxicity Tumors
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The approval of two chimeric antigen receptor-modified T cell types by the US Food and Drug Administration (FDA) for the treatment of hematologic malignancies is a milestone in immunotherapy; however, the application of CAR-T cells has been limited by antigen escape and on-target, off-tumor toxicities. Therefore, it may be a potentially effective strategy to select appropriate targets and to combine multi-antigen-targeted CAR-T cells with "OR", "AND" and "NOT" Boolean logic gates. We summarize the current limitations of CAR-T cells as well as the efficacy and safety of logic-gated CAR-T cells in antitumor therapy. This review will help to explore more optimized strategies to expand the CAR-T cell therapeutic window.
ISSN:	1756-8722 1756-8722